A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...

Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson’s disease, according to a study ...

A recent study suggests that a class of diabetes medications could be linked to a reduced risk of developing dementia ...